Fennec Pharmaceuticals publishes corporate presentation highlighting PEDMARK expansion for cisplatin-induced hearing loss prevention

• Fennec Pharmaceuticals highlighted PEDMARK as the only FDA-cleared therapy to cut cisplatin-induced ototoxicity risk in pediatric patients.
• Presentation cited about a 50% reduction in hearing loss with PEDMARK, with no compromise to cancer treatment in supporting trials.
• U.S. market protection outlined through September 1, 2033, with a European pediatric marketing authorization covering 10 years.
• Global expansion plans include a European partnership with Norgine, Japan registration preparation, plus a GCC partnership with InPharmus.
• Commercial update pointed to 7 consecutive quarters of revenue growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fennec Pharmaceuticals Inc. published the original content used to generate this news brief on August 17, 2026, and is solely responsible for the information contained therein.